Previous 10 | Next 10 |
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. It's not exactly news anymore. Indeed, headlines regarding the new omicron variant of the co...
Vaccine makers have thus far been hesitant to tweak existing coronavirus jabs due fears it could become a game of whack-a-mole, but a super strain may change that sentiment. Testing involving Omicron is already underway among the big manufacturers, with several saying it would take about two ...
Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in n...
VIR's sotrovimab is a monoclonal antibody that binds to a highly conserved domain on the SARS-COV2 virus. The emergence of the South African variant has shown why mAbs are still highly relevant to treating covid-19 patients. Vir's current low prices - despite the small spike recen...
The discovery of a new COVID-19 variant sparked a massive sell-off on Wall Street Friday, with the major averages each plunging more than 2%. However, some parts of the market benefitted from growing concern about a new wave of the virus. For example, stay-at-home stocks received renewed inte...
iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda. RNA interference is...
Britain’s GlaxoSmithKline plc ( LON: GSK ) announced in a joint statement with the U.S. based Vir Biotechnology Inc ( NASDAQ: VIR ) on Wednesday that the U.S. government had agreed to buy about $1.0 billion worth of its antibody-based COVID-19 treatment. U.S. wants GS...
Earnings news remained a crucial driver in Wednesday's pre-market trading. Target (NYSE:TGT) provided a high-profile example, with the stock suffering a bout of profit-taking after the company announced better-than-expected financial figures. Elsewhere, fintech dLocal (NASDAQ:DLO) lost ground...
– US government contracts for approximately $1 billion 1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through binding agreements to more than 750,000 globa...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...